Clinical Trials Sponsored by Merck Sharp & Dohme GmbH, Austria

Total 3975 results

Merck Sharp & Dohme LLC

Completed

EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)

Dementia
Merck Sharp & Dohme LLC

Completed

Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)

Seasonal Allergic Rhinitis
Merck Sharp & Dohme LLC

Completed

Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)

Anesthesia
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)

Bacterial Infections; Virus Diseases
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)

Bacterial Infections; Virus Diseases
Merck Sharp & Dohme LLC

Completed

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

HPV 16 Infection
Merck Sharp & Dohme LLC

No longer available

Post Marketing Surveillance Study of Cuprimine

Scleroderma
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Evaluation Study in Healthy Volunteers

Healthy
Merck Sharp & Dohme LLC

Completed

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Withdrawn

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

Asthma
Merck Sharp & Dohme LLC

Completed

Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145) (MRS Tumor)

Glioma
Merck Sharp & Dohme LLC

Completed

A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)

Obesity
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) (SUPPORT)

Substance Abuse, Intravenous | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)

Healthy
Merck Sharp & Dohme LLC

Completed

Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis
Merck Sharp & Dohme LLC

Completed

Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) (@dhere)

Hepatitis C | Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Rotavirus Efficacy and Safety Trial (REST)(V260-006)

Rotavirus Infections
Merck Sharp & Dohme LLC

Completed

Consistency Lots Vaccine Study (V260-009)

Rotavirus Infections
Merck Sharp & Dohme LLC

Completed

A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)

Glaucoma
Merck Sharp & Dohme LLC

Completed

Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye

Keratoconjunctivitis Sicca
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) (ADEQUATION)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Completed

Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED) (MCAT)

Carotid Atherosclerosis
Merck Sharp & Dohme LLC

Completed

A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)

Acute Coronary Syndrome
Merck Sharp & Dohme LLC

Completed

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

Lymphoma
Merck Sharp & Dohme LLC

Completed

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)

HIV Infections | Acquired Immunodeficiency Syndrome
Merck Sharp & Dohme LLC

Terminated

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) (RE-CHUT)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)

Glioblastoma
Merck Sharp & Dohme LLC

Terminated

Dose-Range Finding Study for MK0893 (0893-008)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
Merck Sharp & Dohme LLC

Completed

A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)

Lung Cancer
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Cholesterol Levels (0524A-048)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Terminated

A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease

Dry Eye Disease
Merck Sharp & Dohme LLC

Completed

A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)

Tumors
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)

Breast Neoplasms | Ovarian Neoplasms | Paresthesia
Merck Sharp & Dohme LLC

Completed

A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)

Cancer
Merck Sharp & Dohme LLC

Completed

Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

MK0524A Phase IIb Study (0524A-011)(COMPLETED)

Flushing
Merck Sharp & Dohme LLC

Completed

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Fenofibrate Bioequivalence Study (0767-031)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)

Chemotherapy-Induced Nausea and Vomiting

3

Subscribe